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Abstract
Background: The goal of this study was to evaluate changes in gene expression in SW-620 cells
in response to SN-38 in order to further elucidate the mechanisms by which SN-38 causes
apoptosis and cell cycle arrest.
Methods: We used a quantitative gene expression microarray assay to identify the genes regulated
by SN-38 treatment in colon cancer cells and confirmed our results with RT-PCR. By gene
expression profiling, we first screened a proprietary list of about 22,000 genes.
Results: Treatment with SN-38 cells resulted in two-fold or greater alteration in the level of
expression of 192 genes compared to control treatment. Most of the affected genes were not
known to be responsive to SN-38 prior to this study. SN-38 treatment of these cells was found to
affect the expression of various genes involved in DNA replication, transcription, signal
transduction, growth factors, cell cycle regulation, and apoptosis, as well as other genes with
unknown function. Changes in expression of 14 genes were confirmed by quantitative real-time
polymerase chain reaction (RT-PCR).
Conclusion: This study leads to an increased understanding of the biochemical pathways involved
in SN-38-induced apoptosis and possibly to the identification of new therapeutic targets.
Introduction
Each year over 50,000 people in the United States die
from colorectal cancer, which is the second leading cause
of cancer death [1]. Although the mortality rate associated
with colorectal cancer has been declining, in part due to
early diagnosis and the introduction of new drugs, present
therapy is often ineffective. Moreover, the majority of the
colorectal cancer cases that are known to be hereditary do
not show a clearly identifiable genetic etiology [2].
Irinotecan (CPT-11) is a chemotherapeutic prodrug that is
converted to SN-38 (its most active metabolite) by carbox-
ylesterases that are abundantly present in the liver [3]. SN-
38 has high anti-tumor activity against refractory solid
tumors, such as carcinomas of the lung, cervix, ovary, and
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between DNA and topoisomerase I, preventing dissocia-
tion of the DNA-topoisomerase I complex and thereby
inducing cell cycle arrest and apoptosis. This mechanism
of action of SN-38 was observed in colon cancer cell lines
[5]. Topoisomerase I functions to unwind portions of the
DNA during replication and transcription by making tran-
sient nicks followed by re-ligation in one strand of the
DNA. SN-38 works to prevent topoisomerase I from
resealing these DNA nicks. As replication continues, per-
manent single strand breaks in the DNA lead to cell death
[6]. SN-38 effectiveness has been directly linked to high
levels of topoisomerase I activity in the cell [7]. Since the
activity of topoisomerase I is usually higher in the tumor
cells than in normal cells, SN-38 action holds some degree
of specificity to tumor cells [6]. Furthermore, a decrease in
expression levels of topoisomerase I in colorectal cancer
cell lines is believed to cause resistance against the effects
of SN-38. In the present study, we investigated the
changes in gene expression that accompany SN-38-
induced colorectal cancer cell apoptosis to evaluate possi-
ble novel signaling pathways involved in this process.
Materials and methods
Cells and culture conditions
Human colon cancer cell line SW-620 was purchased
from ATCC (Rockville, MD; ATCC number CCL-227).
Cells were routinely propagated as a monolayer culture in
Dubbelco's Modified Eagle Medium (Gibco, Invitrogen)
supplemented with 10% heat-inactivated fetal bovine
serum (FBS) and penicillin (100 U/ml)/streptomycin
(100 µg/ml) solution. All cell culture reagents were
obtained from Invitrogen/Life Technologies (Carlsbad,
CA). SN-38 was purchased from Sigma (St. Louis, MO).
Cells were cultured in a 5% CO2 incubator at 37°C and
sub-cultured every 3 to 4 days (when about 80% conflu-
ent).
For experiments, SW-620 cells were plated for 48 h in 4 ×
6-well plates (3 × 105 cells/ well). Cells were then exposed
to SN-38 (50 nM concentration) for 18 h. The control
sample was exposed to vehicle only. For further control of
the effects of SN-38, SW-620 cells were also plated in 1 ×
96-well plate (1 × 104 cells/well) for 48 h. Cells were then
exposed to increasing concentrations of SN-38 (0, 12.5
nM, 25 nM, 50 nM, 100 nM, 200 nM) and samples were
analyzed after 18 h, 92 h, 120 h, and 168 h.
Microarray analysis
cRNA synthesis and labeling
At 18 h after drug exposure, total RNA was isolated with
Trizol reagent (Gibco Life Technologies). We chose a time
point prior to any evidence of apoptosis because we
wanted to investigate the persistent changes in gene
expression in response to SN-38 treatment. First- and sec-
ond-strand cDNA were synthesized from 5–15 µg of total
RNA using the SuperScript Double-Stranded cDNA Syn-
thesis Kit (Gibco Life Technologies) and oligo-dT24-T7
(5'-GGC CAG TGA ATT GTA ATA CGA CTC ACT ATA
GGG AGG CGG-3') primer, according to the manufac-
turer's instructions.
Next, cRNA was synthesized and labeled with biotinylated
UTP and CTP by in vitro transcription using the T7 pro-
moter coupled double-stranded cDNA as template and
the T7 RNA Transcript Labeling Kit (ENZO Diagnostics
Inc.). Briefly, ds cDNA synthesized from the previous
steps were washed twice with 70% ethanol and resus-
pended in 22 µl of RNase-free H2O. The cDNA was incu-
bated with 4 µl of 10× each reaction buffer, biotin-labeled
ribonucleotides, DTT, RNAse inhibitor mix and 2 µl 20×
T7 RNA polymerase for 5 h at 37°C. The labeled cRNA
was separated from unincorporated ribonucleotides by
passing through a CHROMA SPIN-100 column (Clon-
tech) and precipitated at -20°C for 1 h to overnight.
Oligonucleotide array hybridization and analysis
The cRNA pellet was resuspended in 10 ul RNase-free
H2O, and 10.0 µg was fragmented by heat and ion-medi-
ated hydrolysis at 95°C for 35 min in 200 mM Tris-ace-
tate, pH 8.1, 500 mM KOAc, and 150 mM MgOAc. The
fragmented cRNA was hybridized for 16 h at 45°C to
HG_U95Av2 oligonucleotide arrays (Affymetrix, Santa
Clara, CA) containing 22,284 gene transcripts together
with additional probe sets designed to represent EST
sequences. Arrays were washed at 25°C with 6 × SSPE (0.9
M NaCl, 60 mM NaH2PO4, 6 mM EDTA + 0.01% Tween
20) followed by a stringent wash at 50°C with 100 mM
MES, 0.1 M [Na+], and 0.01% Tween 20. The arrays were
then stained with phycoerythrein-conjugated streptavidin
(Molecular Probes), and the fluorescence intensities were
determined using a laser confocal genearray scanner (Agi-
lent). The scanned images were analyzed using Microarray
Suite 5.0 or GCOS software (Affymetrix). Sample loading
and variations in staining were standardized by scaling
the average of the fluorescent intensities of all genes on an
array to constant target intensity (250) for all arrays used.
Data analysis was conducted using Microarray Suite 5.0
(Affymetrix) following user guidelines. The signal inten-
sity for each gene was calculated as the average intensity
difference, represented by [Σ (PM – MM)/(number of
probe pairs)], where PM and MM denote perfect-match
and mismatch probes. Several criteria were used to iden-
tify genes whose expression was affected by SN-38 treat-
ment. First, whether the fold-change of each gene, as
provided by the Affymetrics analysis, was more than 2-
fold up- or down-regulation. The second criterion
employed was whether the difference call, as provided by
the GeneChip software was moderately induced (MI) or
induced (I) for upregulated genes and moderatelyPage 2 of 7
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genes. In addition, only genes in which absolute calls were
double present (or one present – one absent in SN-38 ver-
sus control) were considered as SN-38 responsive genes.
Two completely independent experiments were per-
formed. Only genes that had changed in the same direc-
tion in both experiments with the change p value of <
0.006 were considered for further analysis. The final fold
changes were calculated based on the average signal log
ratio of the two experiments. The genes whose average
expression differed by more than 2-, 5- or 10-fold when
compared to the control treatment were grouped by func-
tional category.
We used the on-line data mining tools from 3 different
software programs: NetAffx Analysis Center (Affymetrix,
Santa Clara, CA), GeneSpring (Silicon Genetics, Redwood
City, CA), and Genesifter (VizX Labs, Seattle, WA).
RT-PCR
At 18 h after drug exposure, RNA was prepared using the
RNeasy mini kit along with RNase-free DNase set to rid
any traces of DNA contamination (both kits were from
QIAGEN, Valencia, CA). cDNA was prepared from 500 ng
of RNA (TaqMan Reverse Transcription Reagents, ABI/
Roche, Branchburg, NJ), based on the manufacturer's
instructions. The template cDNA (12.5 ng/sample) for
control and SN-38 was mixed with Syber green master mix
(ABI). Mixtures were aliquoted into 96-well optical reac-
tion plates (ABI) along with forward and reverse primers
for each target gene. Samples were run in duplicates. The
ABI Prism 7000 sequence detection system was used.
Primers were designed using ABI primer express software.
Amplicon sizes were all below 200 bp. Data were analyzed
using the comparative CT method, which the fold change
of target gene samples (SN-38 treatment) normalized to
the housekeeping gene (beta-actin) relative to the calibra-
tor (control) is calculated by 2-∆∆CT equation, where ∆∆CT
= ∆CT (sample) - ∆CT (calibrator), and ∆CT is the CT value
of the target gene subtracted from the CT value of the
housekeeping gene, all determined in the exponential
phase of the reactions [8]. (PCR primers are listed in Table
1).
Trypan blue cell count and cell cycle analysis
At 18 h after drug exposure, cells from two wells of each
treatment were harvested, and half of them were stained
with trypan blue solution 0.4% (Sigma Chemical Co.) for
5 min. Cells from each of the samples then were counted
using a hemacytometer. The other half of each of the two
samples was washed once with PBS and fixed in 70% (vol/
vol) ethanol at -20°C for up to one week. Cells were pel-
leted, washed once with PBS, and resuspended in propid-
ium iodide (PI) solution (50 µg/ml PI, 0.5 mg/ml RNase
in PBS, pH 7.4) for 30 min in the dark. Flow cytometry
analysis was performed at 18 h after treatment. FACS anal-
ysis was performed on a FACScan flow cytometer (Becton
Dickinson, San Jose, CA, USA). The data from 10,000 cells
were collected and analyzed using CellFIT cell-cycle anal-
ysis software (version 2.01.2).
MTT assay
The MTT assay is also used for the measurement of cyto-
toxicity of a drug. Briefly, SW-620 cells were plated into
96-well plates and treated with increasing concentration
of SN-38 (0 nM, 12.5 nM, 25 nM, 50 nM, 100 nM, 200
nM). We used 1e4 cells in 100 µl of DMEM 10%FBS per
well. After 18 h, 24 h, 96 h, and 120 h of incubation at
37°C, 10 µl MTT (5 mg/ml, Sigma, St. Louis, MO) was
added to each well and incubated at 37°C for 4 h. After
incubation, 50 µl lysing buffer (10%SDS in 0.01 N HCl)
was added, and samples were incubated at 37°C over-
night for complete cell lysis. On the following day, cyto-
toxicity was assessed by measuring the conversion of the
tetrazolium salt MTT to formazan through measurement
of absorbance at 570 nm.
Results
Exposure to SN-38 alters the gene expression in SW-620 
colon cancer cells
At 18 h after treatment, flow cytometry analysis demon-
strated no significant change in G2 cell cycle arrest
between treatment and control. At the same time point,
MTT analysis did not demonstrate any significant differ-
ence in cell viability. After 4 days, MTT analysis showed a
30% decrease in cell proliferation in treated cells com-
pared to the control. Our results are consistent with past
studies that showed SN-38 induces apoptosis in cells with
dysfunctional p53 gene (SW-620 cells are p53 mutant)
[6,9].
In our microarray analysis, after 18 h of SN-38 exposure,
192 genes demonstrated over a 2-fold change in mRNA
expression. Forty of these 192 genes were downregulated,
whereas 152 genes were upregulated. Among those genes,
we found 13 genes with expression change greater than 5-
fold: 10 upregulated and 3 downregulated. Next, we used
NetAffx analysis to categorize all of the altered genes
based on their biological processes and molecular func-
tions, and we found most of the genes to be related to
transcription, DNA replication, signal transduction,
growth factors, cell cycle regulation, and apoptosis. All but
one of the genes related to apoptosis and DNA replication
were upregulated (FAF1 was downregulated).
Little variation was observed in the 840 genes that
changed in both microarray experiments (Fig. 1). We
found 192 genes that had altered expression over 2-fold
and changed in the same direction and with similar fold
changes. In addition, genes that had more than one set ofPage 3 of 7
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expression pattern. We used Miroarray Suite 5 (MAS 5),
Data Mining Tool (DMT), and NetAffx Analysis Center to
categorize the genes according to their biological and
molecular functions. The vast majority of the genes fell
into four categories: cell cycle, apoptosis, signal transduc-
tion, and transcription.
Verification of microarray analysis by quantitative RT-PCR
RT-PCR was performed to confirm the changes in gene
expression observed in the microarray analysis. RNA sam-
ples from all three treatments in each of the two experi-
ments were used to confirm changes. We selected genes
that either had a high fold change in both microarray
experiments or were directly related to apoptotic path-
ways and cell cycle regulation. For all 14 genes tested,
results from microarray and RT-PCR were in agreement
(primers are listed in Table 1). Some genes that had a high
fold change in only one microarray experiment were also
tested. For each of these genes, no change was observed on
RT-PCR.
The two independent microarray experiments behaved similarlyFigure 1
The two independent microarray experiments behaved similarly: Genes demonstrated in this gene tree contain 840 genes 
that changed with a p value < 0.006 in either experiment, indicating whether the genes in the two experiments were upregu-
lated or downregulated in the same direction in both experiments. GeneSpring software (version 6.1) was used for this gene 
tree (Silicon Genetics, Redwood City, CA). Values below 0.01 were set to 0.01. Each measurement was divided by the 50th 
percentile of all measurements in that sample. Each measurement for each gene in the specific samples was divided by the 
median of that gene's measurements in the corresponding control samples. (A full description of these genes and detail of anal-
ysis is available on the GEO repository web site, attachment to Acc. #GSM24425-28). Mock and Pcon are the control sample 
for experiment 1 and experiment 2, respectively. SN-38 and PSN are the treatment sample for experiment 1 and 2, respec-
tively.Page 4 of 7
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of pro-apoptotic pathways, we confirmed the microarray results with real-time PCR using total RNA from 18 h post SN-38 exposure 
of the SW-620 cells and control. Primer express software from ABI has been used to design the primers for real-time PCR (amplicon 
sizes were about 70 bp). Gene symbols and Probe Set ID numbers are as found at the NCBI website http://www.ncbi.nlm.nih.gov and 
NetAffx™ Analysis Center http://www.affymetrix.com/analysis/index.affx. Data are averages from two separate experiments, each in 
duplicate. Data are reported as the fold change of gene expression level SN-38 treated cells versus no treatment control. FC = fold 
change.
Gene Symbol Affymetrix Probe Set ID Primer for RT-PCR RT-PCR avg. FC Microarray avg. FC
β-actin NM_001101 F: CGATCCACACGGAGTACTTG
R: GGATGCAGAAGGAGATCACTG
NC NC
RGC32 218723_s_at F: GAAGCCTTCATTGCTGATCTTG
R: GTCCTCGGAACTTTCTGAAGCT
6.2 6.5
ITGB7 205718_at F: CGGCTCTCGGTGGAAATCTAT
R: GGTCGTGATGGCACTTTTGTAG
3.1 7.8
PDCD4 202731_at F: GTGCTGGAGCGGTTTGTAGAA
R: CCTTCGCTTACAAAACGCTTTC
1.8 2.5
ABAT 209459_s_at F: CTGTTGGTTCAACGTGGTTTCC
R: GCATTTCGGTATCATCTGCCTG
3.4 6.7
DKK3 214247_s_at F: ACCCCTGTCCAGATTATTGGC
R: TTGTTTCCATCTCCTCCCCTC
4.4 6
LYZ 213975_s_at F: CGCTACTGGTGTAATGATGGCA
R: CAAGCTACAGCATCAGCGATGT
4.6 11
CCL20 205476_at F: GTCTGTGTGCGCAAATCCAA
R: CCATTCCAGAAAAGCCACAGTT
3.6 10.6
UBD 205890_s_at F: TTGCAATGGAAAGAGACTGGAA
R: AGGAAGAGTAAGTTGCCCTTTCTG
28.2 17.9
FGF3 214571_at F: AATCAGGGTCCAGTGGGAACT
R: CAAATGCCCTGCATTGCA
-12.6 -5.1






Cyclin E1 213523_at F: CACCAGCCACCTCCAGACA
R: GTGGGAGTCCCTTAGGTCAACTAG
3.1 2.2
Cyclin E2 205034_at F:GAAGTAGCCGTTTACAAGCTAAGCA
R: GCCTGGATTATCTGGGCTTCT
3.2 4.1
TNFRSF6 216252_x_at F: AATCATCAAGGAATGCACACTCA
R: AAGCCACCCCAAGTTAGATCTG
4.2 4.5
Genes involved in apoptotic pathways
Several genes directly involved in apoptotic pathways
were significantly altered. Different isoforms of the
TNFRSF6 gene [tumor necrosis factor (TNF) receptor]
were found to be upregulated. This result is in agreement
with suggestions that SN-38 increases sensitivity of the
cells to TNF-related apoptosis-inducing ligand (TRAIL)
[10]. Other studies detected upregulation of several genes
in the TNF family as early as 2 h after exposure to SN-38
[11]. This indicates that changes in the expression of TNF-
related genes are persistent, and these changes may play
an essential role in induction of apoptosis. Intriguingly,
we found that Fas associated factor-1 (FAF-1), a Fas-bind-
ing pro-apoptotic protein, was downregulated, suggesting
that it does not play a direct role in apoptosis induced by
SN-38 [12-14]. It has been shown that Bax activation, a
pro-apoptotic member of the Bcl-2 family, is required for
TRAIL-mediated apoptosis in colon cancer cells
(HCT116) [15-17]. Other studies have also demonstrated
Bax upregulation after SN-38 treatment in colorectal can-
cer cells [18]. In conformity to these studies, we found
that Bax expression was 2.5-fold upregulated in our exper-
iment. In addition, BNIP3L, a homolog of the pro-apop-
totic protein BNIP3, was slightly upregulated.
Overexpression of both BNIP3L and Bax suggest that SN-
38 may act via the Bax-related apoptotic pathway.
Discussion
Our results showed an increase in expression of three
genes in the cyclin family: Cyclin E1 (CCNE1), Cyclin E2
(CCNE2), and Cyclin G2 (CCNG2). Cyclins are involved
in cell cycle regulation and tumor growth. Previously,
Ueno et al. [19] demonstrated Cyclin E expression is
enhanced after colorectal cancer cells are exposed to SN-
38 and suggested that upregulation of Cyclin E expression
might trigger induction of apoptosis. Our results also
showed a mild upregulation in a variety of cyclin-depend-
ent kinase (Cdk)-related genes, and significant overex-
pression of RGC32, that encodes a protein involved in the
regulation of cyclin-dependent kinase activity that isPage 5 of 7
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has been shown that flavopiridol, a cyclin-dependent
kinase inhibitor, when used in combination with SN-38,
synergistically increases cell death in colon cancer cells
[9]. Our findings suggest flavopiridol might enhance the
apoptotic effects of SN-38 in tumor cells by inhibiting
Cdk and Cdk-related gene activity. Further experiments
are necessary to evaluate the role of Cdk in resistance to
SN-38 therapy and its importance in the regulation of
colon cancer cell death.
SN-38 reduces tumor growth by inhibiting topoisomerase
I function. Interestingly, studies have shown no change in
the level of topoisomerase I mRNA following SN-38 treat-
ment [9,21]. Our results were consistent with these stud-
ies showing that topoisomerase I mRNA upregulation by
SN-38 is not necessary to achieve drug-induced apoptosis.
However, we identified several other genes, not recog-
nized in previous studies, which may be SN-38 target can-
didates. We identified 13 genes with expression altered by
more than 5-fold. The gene with the highest upregulation
is UBD (ubiquitin D, 17.9-fold). Although further studies
are needed to investigate the role of UBD in inhibiting cell
growth in SN-38-treated SW620 cells, UBD expression
may increase via the proteasome pathway degradation of
proteins that induce cell growth. The second highest
expressed gene in SN-38 cells compared to controls is LYZ
(lysozyme involved in carbohydrate metabolism) with an
11-fold change, and third is CCL20 (a chemokine ligand)
with 10.6-fold change. Previous studies have demon-
strated that overexpression of chemokines (including
CCL-20) in murine tumor cells can induce anti-tumor T-
cell responses by recruiting immature dendritic cells
[22,23]. Further studies are necessary to determine
whether CCL-20 behaves in a similar fashion in human
cancer cells. Other genes significantly upregulated were
ITGB7 (involved in integrin-mediated cell adhesion),
ABAT (involved in metabolism, regulation of transcrip-
tion and GENMAPP/KEGG pathway), DKK3 (a regulator
of the Wnt receptor signaling pathway involved in devel-
opment and morphogenesis), PROCR (encodes a receptor
for activated protein C), SGK (involved in protein aa
phosphorylation, sodium ion transport, response to
stress, and apoptosis), and SMARCA1 (which is thought
to regulate the transcription of other genes by interfering
with chromatin structure). Lastly, HIST1H2BE, which
encodes a component of histones, was downregulated
6.1-fold.
Conclusion
Our data confirm and extend the findings of other inves-
tigators and introduces several possible novel pathways to
explain the mechanisms used by SN-38 to induce cell
arrest and apoptosis. SN-38-induced upregulation of cell
signaling receptors may increase the tumor cells' sensitiv-
ity to pro-apoptotic factors, such as TRAIL. Further studies
will be necessary to elucidate the pathways by which SN-
38 signals cells to undergo either cell arrest or apoptosis.
Elucidation of these pathways may lead to the develop-
ment of new drugs to overcome tumor cell resistance to
SN-38 treatment.
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